

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

SM

PPLICANT:

Nicolle Hannah Packer

APPLICATION NO.:

10/528,745

FILING DATE:

March 22, 2005

TITLE:

Method of Identifying Markers Diagnostic of Disease and Uses

Therefore in the Diagnosis of Cancer

EXAMINER:

Not Yet Known

GROUP ART UNIT:

Not Yet Known

ATTY. DKT. NO.:

23681-10204US (Client Ref. 122502)

MAIL STOP AMENDMENT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT Under 37 CFR §§ 1.56 and 1.97-98

SIR:

Pursuant to the provisions of 37 CFR §§ 1.56 and 1.97-98, enclosed herewith is modified form PTO/SB/08A listing references for consideration by the Examiner.

The filing of this Information Disclosure Statement shall not be construed as a representation regarding the completeness of the list of references, or that inclusion of a reference in this list is an admission that it is prior art or is pertinent to this application, or that a search has been made, or as an admission that the information listed is, or may be considered to be, material to patentability, or that no other material information exists, and shall not be construed as an admission against interest in any manner.

This Information Disclosure Statement is being filed:

\boxtimes	within three months of the filing date of the application, or date of entry into
	the national stage of an international application, or before the mailing date of
	a first office action on the merits, whichever event last occurred;
	before the mailing of a first official action after the filing of a request for
	continued examination (RCE) under 37 CFR § 1.114;
	after three months of the filing date of this national application or the date of
	entry of the national stage in an international application, or after the mailing
	date of the first official action on the merits, whichever event last occurred, bu
	before the mailing date of the first to occur of either: (1) a final action under

	37 CFR	R §1.113	3; or (2) an action that otherwise closes prosecution in the
	applica	tion, an	d:
		attache	ed hereto is the fee set forth under 37 CFR §1.17(p) for
		submi	ssion of this Information Disclosure Statement under 37 CFR.§
		1.97(c); OR
		Applic	cant certifies pursuant to 37 CFR § 1.97(e) that:
			each item of information contained in this Information
			Disclosure Statement was first cited in a communication from
			a foreign patent office in a counterpart foreign application not
			more than three months prior to the filing of this Statement;
			OR
			no item of information contained in this Information
			Disclosure Statement was cited in a communication from a
			foreign patent office in a counterpart foreign application and,
			to the knowledge of the person signing this certification after
			making reasonable inquiry, no item of information contained
			in this Statement was known to any individual designated
			under 37 CFR § 1.56(c) more than three months prior to the
			filing of this Statement;
	on or l	efore tl	he payment of the issue fee but after the mailing date of the first
_			ther: (1) a final action under 37 CFR § 1.113; (2) a notice of
			der 37 CFR § 1.311; or (3) an action that otherwise closes
			the application, and:
			cant certifies pursuant to 37 CFR. § 1.97(e) that:
			each item of information contained in this Information
			Disclosure Statement was cited in a communication from a
			foreign patent office in a counterpart foreign application not
			more than three months prior to the filing of this Statement;
			no item of information contained in this Information
			Disclosure Statement was cited in a communication from a
			foreign patent office in a counterpart foreign application and,
			to the knowledge of the person signing this certification after
			making reasonable inquiry, no item of information contained
			in this Statement was known to any individual designated
			under 37 CFR § 1.56(c) more than three months prior to the
			filing of this Statement; AND

PATENT

				attached	hereto i	s the fee	set fo	rth und	er 3	7 CFR	§ § 1.1	7(p) for	r
				submissi	on of th	is Infor	nation	Disclos	sure	State	ment	under 3	7 CFR.§
				1.97(d);									•
			after th	e paymen	t of the	issue fe	e. App	olicant i	requ	ests th	nat the	e inforn	nation
			contair	ned in this	Inform	ation Di	isclosu	re State	mer	nt be p	olaced	in the	file
			accord	ing to 37 (CFR §	1.97(i), a	althoug	h the in	ıforı	matio	n may	not be	
			conside	ered by the	e USPT	Ю.							
	\boxtimes	Enclos	ed is a c	copy of ea	ch liste	d referei	nce tha	t may b	e m	ateria	l to th	e exam	ination of
		this ap	plication	n, and for	which	there ma	ıy be a	duty to	disc	close.			
	☐ This application relies, under 35 U.S.C. § 120, on the earlier filing date of prior					rior							
		applica	ation No)	, filed o	on	, and	d the ref	fere	nces c	ited th	herein a	are hereby
		referen	ced, bu	t are not r	equired	to be pr	ovided	l in this	app	licatio	on un	der 37 (CFR §
		1.98(d)).										
		This ap	plication	on was file	ed after	June 30	, 2003	There	fore	, purs	uant t	to the w	aiver of
		the req	uiremer	nts under i	37 CFR	. 1.98(a)	(2)(i),	copies o	of ea	ach U.	S. Pa	tent and	i each
		U.S. Patent Application Publication are not required to be submitted. Copies of any											
				document		-							
		Each item of information contained in this Information Disclosure Statement was											
				municatio		_	-				-		•
				unication			•	-			_		-
				han thirty			e filing	g of this	s Inf	ormat	ion D	isclosu	re
	\forall			CFR § 1.	` `						0.1.1		•
	[3]			mits that r	no fee is	s require	d for the	ne consi	ıder	ation (of this	s Intorn	nation
	O:			tement.		. 1 6	.1.1			11 - 14	.1		
	Consic	ieration	or the r	isted refer	rences a	ing ravo	rabie a	ction ar	e so	oncited	1.		
					R	Respectfi	ılly sul	omitted,	,				
					N	NICOLL!	E HAN	INAH I	PAC	KER			
Dated:		8/9	4/04		В	By:	fw	m) {	Hor	1		
						usan T.	-	_	o.: 4	7,668	, Pate	nt Ager	nt
						enwick							
						ilicon V 01 Calif	•						
					_	Iountair		· · - · · ·	041				
						el.: (41	•						
					F	ax.: (65)	u) 938-	5200					

3



+

EMP			Apr	olication Number	10,528,745			
				ng Date	March 22, 2005			
TRANSMITTAL FORM				st Named Inventor	Nicolle Hannah Packer			
	nrespondence during pe led application)	endency of	Gro	oup Art Unit Number	Not Yet Kn	own		
			Exa	aminer Name	Not Yet Kn	own		
Total Number of Pag	es in This Submission	6*	Atto	orney Docket Number	23681-1020)4/US		
	FNCL	OSURES	(cl	heck all that apply	/)			
ENCLOSURES Fee Transmittal Form (in duplicate) Check Enclosed Return Receipt Postcard Response to Notice to File Missing Parts Assignment & Recordation Cover Sheet Declaration Power of Attorney Application Data Sheet Information Disclosure Statement & PTO/SB/08A Copies of IDS Cited References (14) Request for Corrected Filing Receipt Request for Correction of Recorded Assignment Amendment/Response: [] Page(s) After Final Status Request Revocation and Substitute Power of Attorney				Issue Fee Transmittal Letter to Chief Draftsperson Formal Drawing(s):				
	SIGNA	TURE OF	ATT	ORNEY OR AGEN	NT			
Signature:	Jun		tw	,				
Attorney/Reg. No.:	Susan T. Hubl, Ph.D.	, Reg. No. 4	3, Patent Agent	Dated:	8/7/06			
		CERTIFIC	ATE	OF MAILING		, (
first class mail in an env If the Express Mail Maili	I hereby certify that this correspondence, including the enclosures identified above, is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. If the Express Mail Mailing Number is filled in below, then this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service pursuant to 37 CFR 1.10.							
Signature:	SH	rhl						
Typed or Printed Nar	me: Susan T. Hubl				Dated:	8/7/06		
Express Mail Mailing Number (optional):								

6	PE	ROB
(AI	1 4 20	
(A)TEN	4 TRAPA	FOR
	S.	ΓΔΤΕ

Substitute for form 1449A/PTO

THEORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application No. 10/528,745

Filing Date March 22, 2005

First Named Inventor Nicolle Hannah Packer

Art Unit Not Yet Known

Examiner Name Not Yet Known

Attorney Docket Number 23681-10204US (Client Ref 122502)

U.S. PATENT DOCUMENTS								
		Document No.						
Examiner Initials*	Cite No.1	Number – Kind Code ² (if known)	Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document				
	Î	US-6,228,654	05-08-2001	Chait et al.				

			FOREIGN PA	ATENT DOCUMENTS	
•		Foreign Patent Document			
Examiner Initials*	Cite No.1	Country Code ³ – Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T _e
		WO 03/016464 A2	02-27-2003	Carbion OY	
		WO 02/08760 A1	01-31-2002	Biotron Limited	
	1:	WO 01/36977 A2	05-25-2001	Matritech, Inc.	

		OTHER REFERENCES - NON-PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T⁵
		BELANGER, A. et al., "Molecular Mass and Carbohydrate Structure of Prostate Specific Antigen: Studies for	
		Establishment of an International PSA Standard," The Prostate, 1995, pp. 187-197, Vol. 27.	
		CAPON, C. et al., "Oligosaccharide Structures of Mucins Secreted by the Human Colonic Cancer Cell Line	
		CL. 16E," The Journal of Biological Chemistry, 1992, pp. 19248-19257, Vol. 267, No. 27.	
		DWEK, M.V. et al., "Oligosaccharide Release from Frozen and Paraffin-Wax-Embedded Archival Tissues,"	
		Analytical Biochemistry, 1996, pp. 8-14, Vol. 242.	
		FUKUDA, M. et al., "Structures of O-Linked Oligosaccharides Isolated from Normal Granulocytes, Chronic	
		Myelogenous Leukemia Cells, and Acute Myelogenous Cells," The Journal of Biological Chemistry, 1986,	
	1	pp. 12796-12806, Vol. 261, No. 27.	
		HOJA-LUKOWICZ, D. et al., "High-Mannose-Type Oligosaccharides from Human Placental Arylsulfatase A	
		are Core Fucosylated as Confirmed by MALDI MS," Glycobiology, 2000, pp. 551-557, Vol. 10, No. 6.	
		International Preliminary Examination Report, PCT/AU03/01063, December 2, 2004, 7 pages.	
		International Search Report, PCT/AU03/01063, November 12, 2003, 4 pages.	
		ITO, A. et al., "A Novel Ganglioside Isolated from Renal Cell Carcinoma," The Journal of Biological	
	1	Chemistry, 2001, pp. 16695-16703, Vol. 276, No. 20.	1

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

	Substitute for f	orm 1449/	A/PTO	Complete if Known				
INFO	DMATION	ו חופ	CLOSURE	Application No.	10/528,745			
			PPLICANT	Filing Date	March 22, 2005			
SIAI	CIVICIAL	o i Ar	PLICANT	First Named Inventor	Nicolle Hannah Packer			
				Art Unit	Not Yet Known			
Submitted on	08/09/06			Examiner Name	Not Yet Known			
Sheet	2	of	2	Attorney Docket Number	23681-10204US (Client Ref 122502)			

		OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T [®]
		LO-GUIDICE, J. et al., "Sialylation and Sulfation of the Carbohydrate Chains in Respiratory Mucins from a	
	ļ	Patient with Cystic Fibrosis," The Journal of Biological Chemistry, 1994, pp. 18794-18813, Vol. 269, No. 29.	ļ
		PERACAULA, R. et al., "Altered Glycosylation Pattern Allows the Distinction Between Prostate-Specific	
	ļ	Antigen (PSA) from Normal and Tumor Origins," Glycobiology, 2003, pp. 457-470, Vol. 13, No. 6.	
•		RAMSAY, S.L. et al., "Determination of Monosaccharides and Disaccharides in Mucopolysaccharidoses	
		Patients by Electrospray Ionisation Mass Spectrometry," Molecular Genetics and Metabolism, 2003, pp. 193-204, Vol. 78.	
•		WONG, N.K. et al., "Characterization of the Oligosaccharides Associated with the Human Ovarian Tumor Marker CA125," The Journal of Biological Chemistry, 2003, pp. 28619-28634, Vol. 278, No. 31.	
			ļ
	ļ		
•			
			i

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached.